Evidence map›Paper›PMID 40195608›Full record

Observational studyClinical endocrinology2025

Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?

Harsha Anuruddhika Dissanayake, Bronwen Warner, Anne-Marie Hannon, Riccardo Pofi, Radu Mihai, Tim James, Brian Shine, David William Ray, Jeremy W Tomlinson, Aparna Pal

Abstract readObservational Study
In one paragraph

Observational study in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Harsha Anuruddhika DissanayakeOxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford, UK.ORCID http://orcid.org/0000-0003-3903-9917
Bronwen WarnerDepartment of Surgery and Cancer, Imperial College London, UK.ORCID http://orcid.org/0000-0003-1897-4682
Anne-Marie HannonDepartment of Endocrinology, University Hospital Limerick, Limerick, Ireland.ORCID http://orcid.org/0000-0001-9049-4945
Riccardo PofiOxford Centre for Diabetes, Endocrinology & Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7808-5735
Radu MihaiDepartment of Endocrine Surgery, Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Tim JamesDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Brian ShineDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
David William RayNIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-4739-6773
Jeremy W TomlinsonOxford Centre for Diabetes, Endocrinology & Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-3170-8533
Aparna PalOxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford, UK.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

objectivePrimary aldosteronism (PA) is the commonest secondary cause of hypertension but case-detection remains a challenge. Screening is usually performed in secondary care using an aldosterone:renin ratio (ARR) measurement. Here, we describe the outcomes of screening in primary care, in Oxfordshire, UK.

designRetrospective observational study. PATIENTS: Adults screened for PA in primary care services in Oxford between 2008 and 2022. MEASUREMENTS: ARR test results in primary care and outcomes of secondary care evaluation (ARR, saline infusion test, final diagnosis). Primary care and secondary care ARR tests were compared for correlation, concordance and performance in predicting PA.

resultsAmong 2915 adults screened in primary care, 455 were referred to secondary care and 107 (3.7% of total population screened) were diagnosed with PA. Primary care ARR showed strong correlation with secondary care ARR (r = 0.841, p < 0.001). Area under the ROC curve to predict PA was 0.81 (95% CI 0.77-0.86) for primary care ARR testing. Primary care ARR cut-off of ≥ 30 pmol/mU showed comparable sensitivity (91.7% vs 92.1%, p = 0.467) to and modest concordance (Kappa 0.583, p < 0.001) with secondary care ARR. Use of beta-blockers were associated with higher risk of false positive test result (OR 3.5, 95% CI 1.1-12.0, p = 0.042).

conclusionsScreening for PA in primary care with ARR is feasible with modest concordance and comparable sensitivity to secondary care testing. Simple referral criteria and raising awareness among primary care colleagues could ensure appropriate referral to secondary care.

Indexed as

HyperaldosteronismMass ScreeningPrimary Health CareAdultAgedAldosteroneFemaleHumansMaleMiddle AgedReninRetrospective StudiesAldosteroneRenincase detectionendocrine hypertensiongeneral practicehyperaldosteronismresistant hypertension

Identifiers

PMID40195608
PMCPMC12223710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.